Venus Remedies Limited - Asset Resilience Ratio
Venus Remedies Limited (VENUSREM) has an Asset Resilience Ratio of 30.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read VENUSREM current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Venus Remedies Limited's Asset Resilience Ratio has changed over time. See shareholders equity of Venus Remedies Limited for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Venus Remedies Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Venus Remedies Limited market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs219.90 Million | 2.86% |
| Short-term Investments | Rs2.14 Billion | 27.89% |
| Total Liquid Assets | Rs2.36 Billion | 30.75% |
Asset Resilience Insights
- Very High Liquidity: Venus Remedies Limited maintains exceptional liquid asset reserves at 30.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Venus Remedies Limited Industry Peers by Asset Resilience Ratio
Compare Venus Remedies Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Venus Remedies Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Venus Remedies Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 21.84% | Rs1.56 Billion ≈ $16.90 Million |
Rs7.16 Billion ≈ $77.40 Million |
+8.47pp |
| 2024-03-31 | 13.37% | Rs838.05 Million ≈ $9.06 Million |
Rs6.27 Billion ≈ $67.79 Million |
+1.38pp |
| 2023-03-31 | 11.99% | Rs720.75 Million ≈ $7.79 Million |
Rs6.01 Billion ≈ $65.00 Million |
+4.18pp |
| 2022-03-31 | 7.81% | Rs453.11 Million ≈ $4.90 Million |
Rs5.80 Billion ≈ $62.71 Million |
+2.55pp |
| 2021-03-31 | 5.26% | Rs292.55 Million ≈ $3.16 Million |
Rs5.56 Billion ≈ $60.11 Million |
+4.94pp |
| 2020-03-31 | 0.32% | Rs20.42 Million ≈ $220.88K |
Rs6.38 Billion ≈ $68.97 Million |
+0.01pp |
| 2019-03-31 | 0.31% | Rs23.01 Million ≈ $248.80K |
Rs7.33 Billion ≈ $79.25 Million |
-0.65pp |
| 2018-03-31 | 0.96% | Rs72.21 Million ≈ $780.93K |
Rs7.51 Billion ≈ $81.20 Million |
-7.66pp |
| 2017-03-31 | 8.63% | Rs715.21 Million ≈ $7.73 Million |
Rs8.29 Billion ≈ $89.67 Million |
+8.30pp |
| 2006-03-31 | 0.33% | Rs2.04 Million ≈ $22.07K |
Rs622.28 Million ≈ $6.73 Million |
-- |
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more